BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:
- 11th Annual Wells Fargo Securities Healthcare Conference at 11:05 a.m. ET on Wednesday, September 7, 2016 in Boston, MA
- Morgan Stanley Global Healthcare Conference at 8:45 a.m. ET on Monday, September 12, 2016 in New York, NY
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://investor.alderbio.com/index.cfm, or by following the links below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
- Wells Fargo link: https://cc.talkpoint.com/well001/090716a_ae/?entity=36_OH41YUV
- Morgan Stanley link: https://cc.talkpoint.com/morg007/091216a_ae/?entity=4_REK0TUS
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide, a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Todd Davenport, Ph.D. Russo Partners, LLC (212) 845-4271 (212) 845-4235 email@example.com firstname.lastname@example.org Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 email@example.com
Source:Alder BioPharmaceuticals, Inc.